Endurant Capital Management LP bought a new position in shares of Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 36,700 shares of the biopharmaceutical company’s stock, valued at approximately $763,000. Endurant Capital Management LP owned approximately 0.07% of Alder BioPharmaceuticals as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Norges Bank bought a new position in Alder BioPharmaceuticals during the fourth quarter worth approximately $5,453,000. Senzar Asset Management LLC bought a new position in Alder BioPharmaceuticals during the fourth quarter worth approximately $2,591,000. Clough Capital Partners L P boosted its position in Alder BioPharmaceuticals by 168.6% in the fourth quarter. Clough Capital Partners L P now owns 468,435 shares of the biopharmaceutical company’s stock worth $9,743,000 after buying an additional 294,035 shares during the last quarter. Guggenheim Capital LLC boosted its position in Alder BioPharmaceuticals by 9.1% in the fourth quarter. Guggenheim Capital LLC now owns 89,980 shares of the biopharmaceutical company’s stock worth $1,872,000 after buying an additional 7,472 shares during the last quarter. Finally, Perceptive Advisors LLC bought a new position in Alder BioPharmaceuticals during the fourth quarter worth approximately $7,991,000.
Shares of Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) traded up 1.60% during mid-day trading on Tuesday, reaching $19.10. 1,543,254 shares of the company’s stock were exchanged. The stock’s market cap is $962.83 million. The stock has a 50 day moving average price of $17.98 and a 200 day moving average price of $20.83. Alder BioPharmaceuticals, Inc. has a 52 week low of $15.10 and a 52 week high of $36.48.
Alder BioPharmaceuticals (NASDAQ:ALDR) last released its quarterly earnings data on Thursday, April 27th. The biopharmaceutical company reported ($1.99) earnings per share for the quarter, missing the consensus estimate of ($0.95) by $1.04. During the same quarter last year, the business earned ($0.76) earnings per share. Equities research analysts predict that Alder BioPharmaceuticals, Inc. will post ($6.40) EPS for the current year.
TRADEMARK VIOLATION WARNING: “36,700 Shares in Alder BioPharmaceuticals, Inc. (ALDR) Acquired by Endurant Capital Management LP” was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://sportsperspectives.com/2017/06/20/36700-shares-in-alder-biopharmaceuticals-inc-aldr-acquired-by-endurant-capital-management-lp.html.
A number of research firms have commented on ALDR. Jefferies Group LLC reaffirmed a “buy” rating and issued a $43.00 target price on shares of Alder BioPharmaceuticals in a research report on Monday, April 17th. Aegis reaffirmed a “buy” rating and issued a $41.00 target price on shares of Alder BioPharmaceuticals in a research report on Tuesday, April 25th. ValuEngine raised shares of Alder BioPharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday. Needham & Company LLC began coverage on shares of Alder BioPharmaceuticals in a research report on Monday, May 15th. They issued a “buy” rating and a $36.00 target price on the stock. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $32.00 target price on shares of Alder BioPharmaceuticals in a research report on Monday, June 12th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $39.00.
Alder BioPharmaceuticals Company Profile
Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.
Receive News & Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.